CluenexBruker BRKR
Bruker scores weak on business quality (4.0 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Bruker does
Bruker builds high-performance scientific instruments and analytical systems, selling to academic researchers, pharma companies, and clinical labs. They generate revenue by outfitting advanced research facilities with mass spectrometers and magnetic resonance systems.
- What it does best
Bruker excels in niche scientific instrumentation, holding a gross margin of 47.7% that outpaces peer AVTR at 31.8%. This edge relies on complex intellectual property in mass spectrometry that academic labs cannot easily swap out without disrupting years of ongoing research data.
- The main risk
High debt load leaves little room for operational missteps, with net debt sitting at $1.57 billion against a backdrop of negative net income of -$107 million. If end-market research funding tightens, debt service will constrain necessary R&D spending.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin rests at 8.6% and net margin dipped to -3.1%, dragged down by rising costs and negative ROE of -2.9%. Scale fails to yield better margins right now.
High switching costs lock in academic and pharma researchers who depend on proprietary hardware ecosystems. Operating margin sits in the sector's lower quartile at 28th percentile, capping the moat's economic power.
Revenue grew at just 2.1% to $3.5 billion, marking a slowdown compared to historical annual expansion rates. The top-line engine is struggling to accelerate.
Net debt sits at $1.57 billion with interest coverage at 4.9x, meaning debt costs consume a notable share of earnings. Free cash flow dropped to $65 million, leaving the balance sheet softer.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
1 sold $198K outside pre-planned sales.
Our sealed record on BRKR
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Bruker scores weak on the Cluenex quality check (4.0 of 10), measured against its own industry. Profitability is weak, moat fair, growth slow and financial health fair.
In the last 90 days of SEC Form 4 filings: 1 sold $198K outside pre-planned sales.
Oct 29, 2026, before the open.
See BRKR today
- Today's verdict on BRKR, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Bruker (BRKR)”, https://cluenex.com/stocks/brkr/, data as of Oct 10, 2026.